Sol-Gel to End SGT-210 Trial in Darier Disease

MT Newswires Live2025-12-18

Sol-Gel Technologies (SLGL) said Wednesday data from its phase 1b trial of SGT-210 in Darier Disease did not show differentiation between SGT-210 and vehicle on efficacy following unblinding.

"The study did not demonstrate a signal of superiority of active treatment versus vehicle," said Executive Chairman Mori Arkin. "We have therefore decided not to advance to the next stage of development in this indication."

Arkin said the firm plans to pursue "very" small, low-cost feasibility studies in other areas where the mechanistic rationale for SGT-210 is strong.

Shares of Sol-Gel were over 2% lower in recent trading.

Price: 41.25, Change: -0.88, Percent Change: -2.08

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592948586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592948586","market":"sh","top_or_hot":-1,"title":"Sol-Gel to End SGT-210 Trial in Darier Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SLGL\">Sol-Gel Technologies</a> (SLGL) said Wednesday data from its phase 1b trial of SGT-210 in Darier Disease did not show differentiation between SGT-210 and vehicle on efficacy following unblinding.</p><p>\"The study did not demonstrate a signal of superiority of active treatment versus vehicle,\" said Executive Chairman Mori Arkin. \"We have therefore decided not to advance to the next stage of development in this indication.\"</p><p>Arkin said the firm plans to pursue \"very\" small, low-cost feasibility studies in other areas where the mechanistic rationale for SGT-210 is strong.</p><p>Shares of Sol-Gel were over 2% lower in recent trading.</p><p>Price: 41.25, Change: -0.88, Percent Change: -2.08</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sol-Gel to End SGT-210 Trial in Darier Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSol-Gel to End SGT-210 Trial in Darier Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-18 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SLGL\">Sol-Gel Technologies</a> (SLGL) said Wednesday data from its phase 1b trial of SGT-210 in Darier Disease did not show differentiation between SGT-210 and vehicle on efficacy following unblinding.</p><p>\"The study did not demonstrate a signal of superiority of active treatment versus vehicle,\" said Executive Chairman Mori Arkin. \"We have therefore decided not to advance to the next stage of development in this indication.\"</p><p>Arkin said the firm plans to pursue \"very\" small, low-cost feasibility studies in other areas where the mechanistic rationale for SGT-210 is strong.</p><p>Shares of Sol-Gel were over 2% lower in recent trading.</p><p>Price: 41.25, Change: -0.88, Percent Change: -2.08</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592948586","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592948586","pubTimestamp":1766002118,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sol-Gel Technologies  said Wednesday data from its phase 1b trial of SGT-210 in Darier Disease did not show differentiation between SGT-210 and vehicle on efficacy following unblinding.\"The study did not demonstrate a signal of superiority of active treatment versus vehicle,\" said Executive Chairman Mori Arkin. \"We have therefore decided not to advance to the next stage of development in this indication.\"Arkin said the firm plans to pursue \"very\" small, low-cost feasibility studies in other areas where the mechanistic rationale for SGT-210 is strong.Shares of Sol-Gel were over 2% lower in recent trading.Price: 41.25, Change: -0.88, Percent Change: -2.08","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SLGL":"Sol-Gel Technologies"},"translate_title":"Sol-Gel将结束SGT-210治疗Darier病的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLGL":1},"content_text":"Sol-Gel Technologies (SLGL) said Wednesday data from its phase 1b trial of SGT-210 in Darier Disease did not show differentiation between SGT-210 and vehicle on efficacy following unblinding.\"The study did not demonstrate a signal of superiority of active treatment versus vehicle,\" said Executive Chairman Mori Arkin. \"We have therefore decided not to advance to the next stage of development in this indication.\"Arkin said the firm plans to pursue \"very\" small, low-cost feasibility studies in other areas where the mechanistic rationale for SGT-210 is strong.Shares of Sol-Gel were over 2% lower in recent trading.Price: 41.25, Change: -0.88, Percent Change: -2.08","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592948586","isCrawlerRequest":true}